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The continuous development of Nanotechnology is progressively introducing nanoparticles into society. 
However, little is known about the safety of nanoparticles and functions of engineered nanomaterials, in 
particular how the physicochemical properties of the materials relate to mechanisms of injury at the nano-
bio interface. While comprehensive knowledge on the potential toxicity of NPs is still lacking, as time goes 
by and research in the field continues, different aspects, such as interactions with the immune system, 
perturbation of cellular membranes, transportation of toxic moieties and others are emerging as potentially 
hazardous aspects of NPs. As a result, this rapidly advancing new field requires the development of novel 
test strategies based on the contribution of toxicological pathways to the pathophysiology of disease that 
allow complex toxicants to be screened in robust, mechanism-based assays in which the bulk of the 
investigation can be carried out at the cellular and biomolecular level whilst maintaining limited animal 
use. A review of these strategies will help to provide guidelines for synthetic nanochemists on how to design 






 Introduction  
The rapidly growing field of nanoscience and nanotechnology has given rise to a new form of material, 
engineered inorganic nanoparticles (NPs), which shows unprecedented potential for revolutionizing many 
fields of materials science and for transforming established technologies. Due to the small size and high 
surface area of NPs, these materials have outstanding electrical, optical, magnetic, structural and chemical 
properties which have been exploited for many new industrial and consumer products.[1-4] Additionally, 
the fact that inorganic NPs are similar in size to intra- and extracellular biological building units, allows 
them to specifically interact with molecular and cellular processes and to manipulate biological states, 
structures and functions in a radical new way, which makes them extremely attractive for biomedical 
applications.[5-9] 
Despite these  opportunities, the widespread use of engineered NPs has created growing concerns about 
their possible adverse effects following intentional and unintentional exposure.[2, 10] Thus, the same 
physicochemical properties that offer great promise to provide scientific and technological breakthroughs 
may also lead to unexpected toxicities not anticipated from materials of the same composition in bulk 
form.[11-13] In this sense, a complete understanding of the size, shape, composition and aggregation-
dependent interactions of engineered NPs with biological systems is lacking[14], thereby provoking keen 
interest in nanotoxicology research.[15, 16] The initial strategy was to address NP toxicity as “new 
chemical substances” and to base safety assessment on established methods for chemical toxicity, including 
a plethora of in vitro assays for cell toxicity, immunotoxicity, and genotoxicity on humans, rodents and 
invertebrates. Resulting studies have reported that in some conditions, engineered NPs may induce 
disparate deleterious biological effects, including membrane permeation, DNA damage, metabolic 
interference, immune exacerbation, inflammation and induction of oxidative stress.[17-21]  
Although frequent attempts have been made to reconcile initial nanotoxicology studies, the toxicity data 
generated is conflicting and inconsistent, resulting in a lack of sufficient significance to confidently  
determine the boundaries for safe use of NPs in commercial products.[22] These limitations are mainly 
related to the diversity of nanomaterials studied, degree of purification, variety of coatings and testing on 
different cell lines under different cell culture conditions, the particular –complex and elusive- behavior of 
engineered NPs and the lack of a commonly accepted comprehensive classification system. A number of 
these studies have focused on traditional toxic nanomaterials presenting a large size distribution, while 
recently engineered NPs with well-defined sizes have been poorly studied.[23] Moreover, much of this 
research has concentrated on empirical evaluation of toxicity with less attention being given to the 
relationships between the physicochemical properties of the material and toxicity thereby limiting 
information for predicting the toxicity of apparently similar NPs. As a result, there is a pressing need to  
optimize synthesis techniques to produce monodisperse materials with controlled variations of single 






methods for in vitro toxicity testing[24] and hence the development and use of validated assays is still a 
critical issue. Finally, despite the increasing body of evidence that pristine NPs can enter and affect 
organisms when dosed under standard exposure scenarios, this evidence often lacks proper exposure 
assessment in terms of the study of the changes undergone by NPs during exposure time. In this sense, there 
is in general a lack of thorough characterization of NPs during their evolution in biological media. 
The potential hazards of engineered NPs, acute or chronic, direct or indirect, are not only determined by 
the physicochemical properties of the engineered NPs per se but also on the interactions of these NPs with 
immediate surrounding environments. As a result, the aim of promoting the timely and safe development 
of engineered NPs, cannot be achieved via traditional studies as they address one material at one time.[25] 
Indeed, engineers produce new materials and products faster than biologists can analyze them, which 
undoubtedly limits the evaluation of their adverse effects. Consequently, the development of a  safer design 
strategy of engineered NPs requires an understanding of both intrinsic (synthetic) properties together with 
their extrinsic responses to external stimuli . On the one hand, it must involve the study of how the intrinsic 
properties, i.e., size, shape, composition and structure of the material, contribute to the potential toxicity of 
the material in question. On the other hand, it must include investigation of the NP evolution in robust, real-
life in vitro and in vivo system models in order to study how these properties are transformed after exposure.  
This is an essential point for understanding the critical biological interactions of NPs, since these 
transformation processes may result in new mechanisms of toxicity[26], including redox activity and 
generation of reactive oxygen species (ROS)[27, 28], dissolution and yielding of toxic ions[29, 30], and 
inflammasome activation.[31] Among them, oxidation-induced damage has emerged as a nanotoxicity 
paradigm[11], promoting the activation of biochemical cascade reactions that can ultimately result in cell 
damage (depletion of reduced glutathione, lipid peroxidation and DNA damage) and even cell death.[32, 
33] In addition, metal ions released from NPs have also been found to cause cell damage, normally as the 
direct consequence of the dissolution of the NPs.[34] Although all these toxicity mechanisms have been 
found to be closely related to the unique physicochemical properties of the NPs (size, shape and 
composition), a satisfactory framework to univocally correlate and anticipate predictive paradigms for 
nanotoxicity has not yet been developed. To this end, new systematic approaches are needed, with the aim 
of determining whether and how the analysis of in vitro and in vivo responses may be used to understand 
the different mechanisms of toxicity and their dependence on the morphological and physicochemical 
properties of engineered inorganic NPs, and whether and how their analysis can be used to develop 
predictive toxicological models.  
Nanosafety aims for a solution through the safer design (and re-design) of nanostructured materials, 
optimizing both performance and safety, by resolving which structural features lead to the desired 
properties and modifying them to avoid their detrimental effects without losing their desired nanoscale 
properties in the process. This solution needs to be considered by taking a comprehensive definition of 






under realistic/controlled exposure conditions and considering both healthy and compromised hosts and 
ecosystems. Moreover, starting with known toxic NPs, the final aim should be the re-design of such 
detrimental specific NP characteristics and to redefine the way they should be manipulated from the 
beginning to the end ot their life cycle. Consequently, known NPs could be used in a safe manner and new 
manufactured ones may be easily evaluated. The idea is to develop the “safety by design” paradigm into a 
practically feasible “safety by redesign” paradigm, which can be implemented for products in the 
marketplace.  
In this context, the focus of this review is to provide an overview of the state-of-the-art of this topic, 
discussing the main strategies and particular aspects to be considered for a predictive “safe by design” 
safety assessment of engineered inorganic NPs. Furthermore, we also provide a brief description of the 
studied structures, their interactions with cells in in vitro cell culture systems, and their potential molecular 
effects (e.g. inflammation), aiming to define the link between these studies and their toxicological effects. 
Towards a Systemic Approach for Assessing Nanosafety of Engineered Nanoparticles 
For the systematic assessment of the potential toxicity of engineered NPs, a multidisciplinary predictive 
approach plan is required, based on a fluid and strong cross-interaction between the different fields involved 
allowing the comparison of results of different studies and ultimately providing guidlines for the re-design 
of safer NPs. Figure 1 illustrates the multidisciplinary approach, which involves four different tasks: i) a 
systematic plan for NP production, analysis and classification, ii) the study of their evolution in the 
physicochemical and biological environments to which they are exposed; iii) the study of their biological 
effects and complex biological responses in healthy and compromised states; and iv) the understanding of 
their fate, transformation and effects in relevant environmental scenarios.  
For the identification of the critical physicochemical properties of the NPs that confer the ability to induce 
an adverse effect in biological systems, data on a wide range of NP models representative of the most 
common ones along with their possible variations is required. This involves the development of widely 
available systematic libraries of NPs to enable both the generation of sufficient datasets for development 
and validation of models and the identification of the physicochemical properties that are involved in the 
different mechanisms of toxicity of these materials.[35, 36] Preliminary data in the literature indicate that 
commonalities of the effects produced by NPs on biomolecules and biological systems allow the 
classification and grouping of a large number of NPs into a few representative families based on 
composition, morphology, functionality, physicochemical state and biological behavior.[37-41] In this 
regard, the use of data repositories for data analysis, data transformation, machine learning and modelling 
is needed to stablish quantitative structure–activity relationship (QSARs) enabling the prediction of NP 
toxicity and toxicity mechanisms.[42-44] 
Furthermore, it is also important to investigate not only the biological response from cells and organisms 






ecological environments.[45] Traditionally, NPs have often been treated as stable objects. However, NP 
evolution is now being accepted, as for example in the case of identification of formation and dynamics of 
the protein corona when exposed to biological fluids, aggregability of NP (previously observed but largely 
ignored) and dissolution which are being acknowledged as critical when assaying NP safety.[46]  
 
Figure 1. Schematics of the synergy between fundamental concepts. The multidisciplinary systemic 
approach to assess nanosafety of engineered NPs involves four different tasks: i) a systematic plan for NP 
production, analysis and classification (A), ii) the study of their evolution in the physicochemical and 
biological environments to which they are exposed (B); iii) the study of their biological effects and complex 
biological responses in healthy and compromised states (C); and iv) the understanding of their fate, 
transformation and effects in relevant environmental scenarios (D).  
 
The following section includes a summary of the current efforts to develop a systematic plan for NP 
production, analysis, and study of their evolution in the physicochemical and biological environments to 
which they are exposed together with the reported strategies for study of their biological effects and 
complex biological responses. A description of the current in vitro and in vivo analysis techniques will also 
be discussed within the context of the ongoing challenges and recommendations made for achieving more 







1. Development of combinatorial libraries of NPs  
To date, only a few NPs have undergone safety studies while many others have never been tested, or not 
tested in particular formats that would allow comparing their effects. Therefore, for a predictive 
toxicological approach, a description of sufficient variation in materials and properties is needed. Indeed,  
comprehensive knowledge of nanomaterial not only from composition and morphology but also from a 
chemical and physical perspective is critical, since physicochemical properties are strongly coupled to their 
composition and morphology. For this purpose, the development of combinatorial libraries including 
systemic variation and accentuation of physicochemical properties is highly desirable not only to provide 
a robust platform to study the correlations between materials properties and toxicity but also to incorporate 
and renormalize the material data from different sources for hypothesis validation and development of 
toxicity models.[47] Significantly, an important challenge is the minimization of variability in 
manufacturing methods[48], the development of robust and reproducible synthesis strategies[49, 50], and 
the reaction scaling necessary to produce adequate volumes of uniform NPs.[51]   
Through the control of NP synthesis, it is possible to derive thousands of variations by changing 
composition, size, shape, surface chemistry (charge and functional group), and crystal structure, aging state 
and other factors, as the model shows in Figure 2. Among the parameter variables, size is especially 
interesting since it is with the smaller size range (from a few to 100 nm) where most novel phenomena 
occur due to surface, quantum confinement and finite-size effects. Indeed, the size dimension of NPs has 
been found to be a critical parameter in determining the behavior and fate of NPs in biological systems.[52, 
53] Although some studies claim that the nanoparticle-mediated cellular response is size-dependent[54, 
55], others disagree that it plays such a critical role.[56] These inconsistences result from the limited number 
of samples tested in each particular study, covering a limited size range, and/or the particular cellular 
response studied.[55] Moreover, other properties such as morphology and crystal structure need to be 
carefully evaluated and kept invariable when the size effects are studied. This is particularly important in 
those NPs known to be highly sensible to morphology and crystal phase transformation as the size changes 
since the specific arrangement of atoms has been found to be closely relevant to their potential oxidative 
reactivity.[57] As a result, it has been shown that NPs present a different reactivity with respect to various 
crystal morphologies and structures which ultimately affects total cell uptake and toxicity.[58] A well-
known example is TiO2 in which both rutile and anatase crystal structures exhibit the same chemical 
composition but a different crystalline structure, being proved that the levels of toxicity and the mechanism 
of cell death depend on this crystalline structure.[59] Other than primary size, NPs also serve as a model 
for many solid state nanomaterials (especially metals and metal oxides) whose nanostructured surface or 
body may be considered as an aggregate (ordered or not) of NP-like units. In these systems, the aggregation 








Figure 2. Development of combinatorial libraries of NPs. Combinatorial libraries of engineered 
inorganic NPs can be built through the control of NP synthesis varing the major physicochemical 
properties involved in toxicity. Property variations include nanoparticle size, shape, composition, porosity, 
crystal structure, surface state, agglomeration statea and size distribution. A single property variation may 
also change other properties which has to be carefully evaluated. 
 
The particular characteristics of NP surface chemistry has been found to be another critical parameter 
altering the behavior and fate of NPs in biological systems which can be controlled during their 
synthesis.[62, 63] Since NPs can be produced with different functional groups on their surface, by 
modifications of NP’s surface coating, charge and hydrophobicity their reactivity may be modified, 
improving the stability of the colloidal sample and ultimately altering their interactions with the (biological 
or ecological) surrounding, ultimately increasing or decreasing their toxicity towards cellular or biological 
organisms.[30] It is worth mentioning that when NP charge is altered, often, the pH or the chemical nature 
of the ion/molecule that bears these charges also changes, illustrating how at this scale, charge and surface 
state are strongly coupled. The same argument can be applied to shape control since, commonly, different 
shapes are obtained because of the choice of different surfactants. In this sense, when preparing the NP, it 
is important to understand that a change in size and shape often leads to a change in surface state and vice 
versa. 
2. Physicochemical transformations of NPs in physiological environments.  
Since the properties of engineered NPs are strongly determined by both intrinsic (synthetic) and extrinsic 
(environmental) aspects, the study of the physicochemical transformations of engineered NPs in the 
particular context in which they are immersed represents a cornerstone in the development of a knowledge 
base on predictive and actual nanosafety.  Due to their higher percentage of surface atoms and their colloidal 
nature, NPs experience processes that transform them towards more stable thermodynamic states[18, 64], 






nature of the nano-bio interface (Figure 3).[64-70] From the NP point of view, these interactions can cause 
phase transformations, particle aggregation, reconstructuring and dissolution. All of these processes have a 
significant influence on the reactivity, bioavailability and pharmacokinetics of NPs[71], affecting their 
persistence and ultimately leading to toxic effects.[66, 72-74] For example, extracellular agglomeration of 
NPs, or the agglomeration occurring prior to or during exposure to in vitro or in vivo toxicity testing, has a 
significant impact on the observed toxicological effects and conclusions about their size-dependent 
toxicity.[60, 75] In this regard, one interesting trend found was that with most NPs tested, the addition of 
serum to the cell culture media helped to mitigate the tendency and effects of NP agglomeration.[76, 77] 
From the biomolecules point of view, these interactions may lead to the opsonization, formation of Protein 
Coronas (PCs) of a different nature[77-80] (the so-called soft and hard corona), denaturation of 
proteins,[81] and the formation of NP-protein complexes,[79] which inevitably provide them with a new 
biological identity,[82, 83] eventually promoting the activation of signaling pathways[84-86] and 
ultimately determining their physiological response and toxicity.[87, 88] The impact of the protein corona 
on cytotoxicity, and immunotoxicity has been widely studied. We refer the reader to a number of excellent 
reviews on each of these topics.[30, 87-91] 
 
 
Figure 3. Examples of physicochemical transformations of the properties of engineered inorganic 
nanoparticles immediately after their synthesis (aging) and/or after their exposure to 
biological/ecological environments. To elucidate the mechanisms of biological action of NPs, 
physicochemical transformations, including dissolution, oxidation, homoaggregation and 
heteroaggregation (interaction with proteins) must be carefully considered and comprehensive 







Due to the evolution described above, the evaluation of the properties of as-synthesized materials does not 
actually represent the properties of the materials during or following their biological or ecological exposure. 
Consequently, a comprehensive characterization of NP properties during their full life cycle is needed in 
order to determine their contribution to toxicity.[92, 93] Intense efforts have been devoted to understanding 
the particular time-dependent evolution of as-synthetized NPs in the immediate surrounding 
environment.[70] Some of them have addressed this point by a combination of analytical techniques[72, 
84, 94] and/or analyzing the atomic and electronic structure of NPs coupled to coordination chemistry 
studies.[95, 96] These analyses has given insight into the electrochemical properties of the NP core in 
relation to the production of ROS.[97] Other approximations have included modelling studies of NP surface 
interactions with other NPs and proteins, with the aim of understanding the formation process of the PCs 
or NP aggregates.[98] In all cases, these analyses have to be designed to incorporate and compare the 
available data for rationalization. Undoubtedly, the development of systematic exposure protocols and 
reliable methods for assessing NP internalization and their kinetics in living organisms may allow a full 
description of the exact nature of NP toxicity in the near future. 
3. Evaluation of the Biological Impact of Engineered Inorganic Nanoparticles 
Addressing how the adverse effects of engineered NPs translate and progress up the layers of biological 
complexity, covering molecular to cellular, organ to organism and individual to ecological levels is of 
crucial importance to determine the final impact of NPs. In this respect, biological evaluation has to cover 
all of these stages, from molecular pathways, cell biology and advanced in vitro systems up to in vivo 
models, from a particular point-of-entry to multi-exposure scenarios (Figure 4). Among them, of special 
relevance is the large size of NPs compared to small molecules and the effects that they may have on 
permeability and barrier interaction of NPs in biological tissues, since ultimately, NPs need to cross barriers, 
like the cell membrane, skin and mucosal barriers, to fully express their biological impact. 
3.1. The Effect of Nanoparticle on Cellular Behavior 
Cell functions depend on assembly forces.[70] Therefore, besides obvious toxicity[99, 100], more subtle 
effects of NPs on cells may have important implications for their impact on biological systems. In this 
sense, a systemic approach for assessing nanosafety of engineered NPs should include the study and 
analysis of the broad spectrum of different NP–cell interactions[70, 101] and their impacts on much 
different cellular physiology function levels (such as mitochondria, ROS production, cytoskeletal, 
intracellular calcium, and membrane currents).[102] 
There are indications that the direct toxicity of NPs can be related to their ability to interfere with the normal 
functioning of the plasma membrane.[103-105] In this regard, biomembrane models have been widely used 
for the study of NP-cell interactions and how this affects the self-assembly and organization of their 
structure (Figure 5). Interesting examples include the study of the interactions between the NP and model 






trafficking and exit of NPs[19, 108], further extended to cellular systems.[19, 108] Although some of them 
were designed to systematically evaluate the specific NP properties which influence their interaction with 
the cell membrane, especially after their unintended (protein corona) or intended (functionalization) 
coating[13, 37, 109, 110], at present, there is a dearth of understanding of the particular correlation of the 
biological response with the physicochemical properties of the NPs involved.[37] Moreover, further 
evidence on whether and how these properties may or may not be stressful for the cells (“latent toxicity”) 
are still poorly understood.[109] This lack of understanding is in part due to complex behavior of engineered 
NPs in biological systems and the fact that mechanisms that govern cell internalization of NPs are also 
dependent on the cell type[109, 111] Indeed, the fate of NPs within cells often involves processes of 
aggregation and dissolution, and protein coating, limiting the significance of obtained results.[70] In this 
sense, the characterization of the reactivity of the NPs before and after internalization is also critical for 
understanding their cellular uptake and intracellular trafficking.[109] 
 
Figure 4. Evaluation of the Biological Impact of Engineered Inorganic Nanoparticles from molecular 
pathways, cell biology and advanced in vitro systems up to in vivo models, from a particular point-of-entry 
to multi-exposure scenarios is of crucial importance to determine the final impact of NPs. 
 
In parallel, the response of the cell in the presence of NPs has been also widely studied. Cellular homeostasis 
is maintained by a complex network of signaling molecules. Therefore, graver disturbances leading to the 
induction of defense programs are important aspects to study. In this sense, if it is known which receptors 
or pathways are affected in response to defined properties of NPs, it may be possible to modify the NP 
accordingly to avoid recognition or to induce tolerogenic signals. Since the immune system is responsible 
for categorizing external invasions and organizing defenses, it is especially suited for these studies. 
Intensive efforts have been devoted to clarifying which of numerous possible mechanisms for the induction 
of cell stress, inflammation and apoptosis are specific for a particular type of NP.[112] This has been 
assessed by investigating changes in gene expression[113] which have provided important information 






associated with the time-dependent fate of NP within the cell. Concentrations of selected metabolites have 
been found to be affected by the presence of NP by direct means (adsorption), or indirectly, like protein 
concentrations by changes in transcription.[114] Metabolites reflecting immunity, cell stress and apoptosis 
are also interesting parameters studied.[115] Similarly, the study of interactions between NPs and DNA, 
and further quantification of DNA damage and DNA repair activities in response to NP exposure were also 
the subject of interesting studies.[116] The reactivity of NPs of various compositions and coatings were 
studied with isolated DNA and in cells identifying and classifying selected NPs according to their DNA 
damaging, and oncogenic potential, by direct damage to DNA or by inducing chronic inflammation.[117] 
These experiments, using a large number of NPs and a variety of cells and endpoints gathered together and 
analyzed, have allowed determining minimum parameters to set a screening platform for NP-cell 
interaction.[118]  
 
Figure 5. Interactions of Nanoparticles with Cell Membranes. Direct toxicity of engineered NP can be 
related to their ability to interfere with the normal functioning of the cell membrane. After exposition of 
inorganic NPs to biological scenarios, NPs may interact with and cross biological membranes leading to 
membrane disruption, leakage, rupture and perforation. The study and understanding of these processes 
are key mechanism in determining their effects on biological cells.  
 
When assessing NP-cell interactions, another aspect to consider is the testing of the effects of NPs 
functionalized with toxins and contaminants that may be realistically present during synthesis (e.g. 
lipopolysaccharide (LPS)) or of very different origins (e.g. airborne seasonal allergens), in order to study 
long-term effects of contamination, in particular when assessing nanoimmuno interactions.[20, 119]  For 
in vivo studies (where long-term exposures are assessed), sterilization of the NP represents a greater 
challenge since autoclaving may cause massive aggregation and chemical methods may alter the NP surface 
and induce unwanted effects such as corrosion in metals and even toxicity. UV light, another commonly 








3.2. The Effect of Nanoparticle on Biological Systems 
NPs may enter the human body via various routes, including respiratory pathways, digestive tract, skin 
contact, intravenous injection, and implantation.[120] After absorption from inhalation, oral, or cutaneous 
routes, NPs might translocate in the systemic circulation being delivered to various organs and tissues, 
including liver, spleen, kidneys, heart and brain by the bloodstream and the lymphatic system.[52, 99, 121] 
Although some ingested or absorbed NPs are metabolized and excreted, others remain accumulated in the 
body for a long time.[99] The determination of absorption, distribution, metabolism and excretion (ADME) 
rates of nanoparticles is essential for evaluating potential toxic effects.[122] The route of administration 
greatly determines the accumulation and elimination of NPs. If the particle is injected orally, they mainly 
accumulate in intestinal organs (e.g., liver and spleen) and are further eliminated through feces, whereas 
after parenteral or intravenous administration, they are mostly eliminated via the kidney while traveling 
through the blood. Moreover, the drainage of NPs through different organs also depends on the 
physicochemical properties of the NPs. Thus, if the NPs are <20 nm, they can easily be cleared up by the 
normal drainage organs, such as the kidney (<5 nm) or the liver (10–20 nm) while larger particles (<200 
nm) are eliminated by the reticulo-endothelial system (RES), being eventually accumulated in the spleen, 
bone marrow, and other RES which may cause systemic toxicity.[123, 124] Although the lungs is not a 
conventional eliminatory system, it can help in filtering aerosolic NPs with sizes >100 nm. In this case, 
alveolar macrophages and mucociliary transporters are the main mode of excretion.[121] This macrophage-
mediated clearance is size, and surface property selective.[125] A small numbers of NPs can also enter 
organs that are protected by dedicated barriers, such as the brain[126, 127] and the testis.[128] It is not only 
size and aggregation state that matters in the excretion and clearance, but also surface properties.[121, 129] 
Thus, polyethylene glycol (PEG) coating reduces the connection with plasma proteins and results prolonged  
circulation  time,  which  decreases  the immediate  accumulation.[130] Readers can refer to some recent 
review papers summarizing the relationship between NP’s physicochemical properties and their in vivo 
behaviors and fate.[45, 121, 131]  
As evidence, it is emerging that the route of entry, and the particular physicochemical properties of  NPs 
(composition, size, shape, surface properties and aggregation state) play a distinct role in determining the 
organ biodistribution of NPs, and further, that complete understanding of the NP bioresponses is too 
complex to be fully framed in standard 2D mono-type cell culture models. Therefore, for the development 
of a predictive “safe by design” approach for engineered inorganic NPs, new biological models to assess risk 
and determine safety practices are needed. This includes the establishment of 3D co-culture models of 
primary cells, either based on tissue or on induced pluripotent stem (iPS) cells[132], to study complex 
responses, and compare health vs. compromised states. Although, a considerable number of the toxicological 
studies conducted to date have been performed using transformed cell lines, primary cell cultures are closer 
to the in vivo situation and show greater variability reflecting the reality of biological systems.[133] In this 






of the donors, including disease states, and the ability to be differentiated into many cell types. As 
previously mentioned, the implementation of high-content and high-throughput screening (HCS and HTS) 
approaches to compare batches of materials, ranging from a few (10-20) to many (100-200) in each 
comparative analysis, has been of crucial importance in order to compare a wide material range and test 
multiple concentrations of each batch of NP material to cover a wide dose range.[17, 118] Among the 
different HTS approaches, interaction with zebrafish embryos/larvae and complement activation in different 
biological fluids have been especially interesting for initial assessment of NPs in complex biological 
models.[134, 135] The zebrafish test has become a widely used model for toxicology studies, largely 
reflecting early development of human and other vertebrates that allow large-scale testing of NPs.[136] More 
complex in vitro advanced models, including multicellular models of respiratory and gut mucosa, skin, 
liver, kidney, heart, brain, and blood have been developed, suitable for evaluating the overall mechanisms 
of interaction with selected NPs.[100, 137] Importantly, each model has to be evaluated in physiological 
conditions and upon challenge, to reproduce the behavior in healthy vs. diseased conditions.  
Remarkably, most in vivo and in vitro models currently available for assessing hazard, exposure and 
consequent risk are based on healthy organisms/conditions. However, this is a widely unrealistic 
assumption since during the course of disease, the body barriers may be altered, the biochemistry modified, 
the redox state of the tissue changed (e.g.: hyperoxia during inflammation and hypoxia in solid tumors), 
and the cell defense mechanisms weakened. All of these situations may make NPs that were non toxic in 
healthy conditions become so. In this regard, the analysis of subtle -but critical- effects, which escape the 
screening performed in simple models, and the study of prolonged exposure studies (including 
accumulation, repeated doses and memory) which actually disrupt normal activity and lead to posterior 
malfunctioning and diseases, have been found of crucial importance for a systemic and robust approach for 
assessing the nanosafety of engineered NPs.[25]  
For events that cannot be modelled in vitro with human cells - developmental, ADME (absorption, 
distribution, metabolism, and excretion), validation of disease conditions -  relevant in vivo animal models 
have also been used. A few recent studies have focused on in vivo biodistribution of engineered NPs as it 
relates to their physicochemical properties.[45] Although in these studies the location of NPs at different 
time points and at different doses were quantitatively mapped, thus far, no general conclusion has been 
reached  as to how size, shape, aggregation and surface chemistry affect NP bio-distribution.[99] 
4. Nanoparticles and Environment  
The increase in the production and use of engineered NPs has made exposure of these compounds to the 
natural environment more and more likely. As a result, the evaluation of the environmental risk of 
engineered NPs has been included in the systematic evalatuion of their safety assessment.[138, 139] NPs 
can be released into the environment, either directly through their use, for instance in soil remediation or 






accidents.[140] Within their life cycle, the environmental release of NPs is of importance for two main 
reasons. First, because NPs may interact with soil, sediment, water, air or any other environmental 
constituent, potentially transforming their properties and behavior beyond those previously considered. 
Second, because NPs interact with organisms and may accumulate within them and affect their functioning. 
Mechanisms between NPs and biological entities occurring inside a living body are analogous and 
complementary to what happens in the environment. In this sense, the exploration of how NP design 
features (structure, surface, coating etc.) help to govern the entry, passage and fate (reactions and ageing) 
of NPs in the environment and organisms have been an important focus of attention.  
Charting what happens to NPs released in various reactive parts of the environment and linking this to 
effects across species of increasing complexity, has been reported as key to understanding what NP 
properties control how NPs enter organisms, distribute, accumulate, transform and cause effects. A major 
route of environmental release of NPs is considered to be domestic and industrial wastewater. Several 
studies have addressed the study of the fate, transformation and effects of NPs in wastewater treatment 
plants (the environmental gatekeeper for NPs used in consumer products), where NP fate and 
transformation was tracked after their exposure to this highly reactive environment.[141-143]  Similarly, 
the behavior of NPs has been studied in fresh and marine aquatic environments of greatly varying chemistry, 
and the effect studies included potentially exposed organisms covering all possible uptake routes (e.g. 
biofilms, filter & sediment feeders/dwellers) and predators (bacteria, algae, Daphnia, insect larvae, mud 
shrimps, mussels and fish).[144-146] Studies were extended to small-scale terrestrial ecosystems, 
mimicking environmental conditions, allowing long-term (years) and realistic low dose exposures of 
several species (microbes, crop plants, invertebrates with different living and feeding habits, and guilds) 
simultaneously, as well as evaluation of soil function and leachate collection in time (route to 
groundwater).[138, 144]  
 
Conclusions and Outlook  
The rapidly advancing field of nanoscience and nanotechnology is univocally associated with growing 
concerns about their possible adverse effects following intentional and unintentional exposure. In this 
regard, a system for the systematic assessment of the potential toxicity of engineered NPs is required. Such 
a system needs to be based on a multidisciplinary predictive approach plan with a fluid and strong cross-
interaction between the different fields involved. In this review, we have summarized recent developments 
of novel nanosafety strategies addressing the “safe-by-design” paradigm for optimizing both performance 
and safety, allowing the comparison of results of different studies and ultimately providing guidelines for 
the re-design of safer NPs. We have identifiyed four different tasks involved, including a systematic plan 
for NP production, analysis and classification,  the study of their evolution in the physicochemical and 






and compromised states, and an understanding of their fate, transformation and effects in relevant 
environmental scenarios. The resulting discussion is intedend to provide guidelines for synthetic 
nanochemists on how to design NPs to be safe during their full life cycle while maintaining their parental 
desired properties. 
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